ClinVar Miner

Submissions for variant NM_001876.4(CPT1A):c.1393G>A (p.Gly465Arg)

gnomAD frequency: 0.00001  dbSNP: rs80356784
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000666810 SCV000791166 uncertain significance Carnitine palmitoyl transferase 1A deficiency 2017-05-01 criteria provided, single submitter clinical testing
Invitae RCV000666810 SCV001495634 likely pathogenic Carnitine palmitoyl transferase 1A deficiency 2023-10-19 criteria provided, single submitter clinical testing This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 465 of the CPT1A protein (p.Gly465Arg). This variant is present in population databases (rs80356784, gnomAD 0.004%). This missense change has been observed in individual(s) with carnitine palmitoyltransferase I (CPT1) deficiency (PMID: 27066452). ClinVar contains an entry for this variant (Variation ID: 551684). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CPT1A protein function. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This variant disrupts the p.Gly465 amino acid residue in CPT1A. Other variant(s) that disrupt this residue have been observed in individuals with CPT1A-related conditions (PMID: 15110323, 32781271), which suggests that this may be a clinically significant amino acid residue. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Natera, Inc. RCV000666810 SCV002092952 uncertain significance Carnitine palmitoyl transferase 1A deficiency 2020-12-04 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.